|1st September 2020||Lp Bleichroeder||250,000||Open or private sale||$1.68||$420,000.00|
|21st August 2020||Jon S Saxe||30,000||Open or private purchase||$0.69||$20,700.00|
|3rd June 2020||Judy R Joice||34,864||Exercise of derivative||$0.78||$27,193.92|
|3rd June 2020||Judy R Joice||22,956||Open or private sale||$2.45||$56,283.52|
|3rd June 2020||Judy R Joice||22,956||Exercise of derivative||$0.78||$17,905.68|
|3rd June 2020||Judy R Joice||34,864||Open or private sale||$2.45||$85,479.56|
|26th May 2020||Lp Bleichroeder||39,388||Open or private sale||$2.50||$98,525.14|
|27th March 2020||Lp Bleichroeder||10,325||Open or private sale||$4.09||$42,199.31|
|26th March 2020||Lp Bleichroeder||17,175||Open or private sale||$4.40||$75,540.80|
|18th March 2020||Lp Bleichroeder||34,066||Open or private purchase||$2.34||$79,785.98|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
DURECT Corp. engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine.